BOUL Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. It operates through Diagnostics and OEM Clinical Diagnostic Solutions. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms. The company was founded in 1956 and is headquartered in Spånga, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Boule Diagnostics (STO: BOUL)
›
Boule Diagnostics (STO: BOUL) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 200 employees.
The shares were at 1.235 SEK on 19 November 2026, down 79.4% over 52 weeks. Its 52-week range is 0.8400 SEK to 6.260 SEK: the price is 80.3% below the high and 47.0% above the low.
Its market capitalisation is 47.96M SEK.
Boule Diagnostics reports return on equity of -2.2%, an operating margin of 2.4% and revenue down 24.4% year over year.
Its debt exceeds its cash by 203.00M SEK, a debt-to-equity ratio of 1.33. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 3.800 SEK is 207.7% above the current price.